Acutaas Chemicals Q1 FY27 Results: Date, Call Time

Why Acutaas’ Q1 FY27 print matters

Acutaas Chemicals Limited (NSE: ACUTAAS) heads into its Q1 FY2026-27 results after a year marked by aggressive capacity additions and sharp sequential revenue growth through FY2025-26. The immediate market focus is whether the company can sustain its elevated exit run-rate from Q4 FY2025-26 while managing margin headwinds from a higher depreciation base and a bulk chemicals pricing environment described as stabilising.

Investors are also likely to look for management’s update on commissioning timelines for new projects, progress on battery chemicals and CDMO ramps, and any commentary on demand trends across the company’s end markets.

Results date and board meeting schedule

The company is scheduled to hold a board meeting on July 24, 2026 to consider the audited financial results, as per the provided material. Separately, some trackers referenced an indicative July-August 2026 window for the Q1 FY27 results season, and another mention pointed to July 29, 2026 as the next earnings date.

Given these multiple references, investors typically confirm the final result date and documents using NSE/BSE filings and the company’s announcements.

Earnings call time and who will be on the call

Acutaas Chemicals has scheduled an earnings conference call on Friday, July 24, 2026 at 4:00 PM IST to discuss its unaudited financial results for the quarter ended June 30, 2026. The call is hosted by Nuvama Wealth Management.

The management participants listed for the call include:

• Naresh Patel – Chairman and Managing Director
• Bhavin Shah – Chief Financial Officer
• Abhishek Patel – President (Strategy)

The call leader is Archit Joshi of Nuvama Wealth Management Ltd, and the contact email shared is Archit.Joshi@nuvama.com.

Dial-in access numbers provided include:

• India (Mumbai): +91 22 6280 1123, +91 22 7115 8024
• USA: +1 866 7462 133
• UK: +0 808 1011 573
• Singapore: +800 1012 045
• Hong Kong: +800 9644 48

Quick snapshot: where Q4 FY26 left the company

The company’s FY2025-26 quarterly revenue ramp is one of the key context points going into Q1 FY2026-27. The material states revenue rose from Rs. 207 crore in Q1 to Rs. 432.75 crore in Q4. Q4 revenue of Rs. 432.75 crore was also described as sequential growth from Rs. 393 crore in Q3.

Profitability in Q4 FY2025-26 was also highlighted, with PAT of Rs. 131.76 crore, compared with Rs. 62.5 crore in Q4 FY2024-25.

What investors are likely to watch in Q1 FY27

One watchpoint is whether the strong Q4 exit run-rate translates into stable near-term revenue despite commentary that bulk chemicals pricing has entered a consolidation phase. Management commentary on demand, product mix, and any seasonality effect is expected to shape the market’s view of near-term execution.

Another key issue is margins. The material notes possible pressure from increased depreciation as the company capitalises Rs. 332.3 crore of capital work-in-progress. Separately, a total FY2025-26 capex spend of Rs. 328.0 crore is cited in the preview narrative.

Investors will also track updates on commissioning schedules for new capacities and how quickly new projects translate into billable volumes.

Capex, capacity additions, and depreciation sensitivity

Beyond the preview narrative, the provided management commentary includes multiple capex datapoints for FY27 planning. One section notes planned FY27 capex of around Rs. 100 crore, including spillover and maintenance, with additional R&D centre capex to be finalised.

Another section references FY26 capex of Rs. 195 crore focused on the Jhagadia site for a battery chemical project and a pilot plant at the Sachin site, plus maintenance. It also mentions spillover capex of around Rs. 50 crore in FY27 and planned FY27 capex around Rs. 90 crore (spillover plus maintenance), excluding new R&D centre costs.

Because depreciation typically rises as capex moves from CWIP to commissioned assets, the Q1 FY27 commentary on capitalisation timelines and utilisation rates can be important for interpreting margins.

Balance sheet position: net cash highlighted

The company’s balance sheet position was described as strong, with net cash of approximately Rs. 189 crore at the end of Q4 FY2025-26. This was broken down as Rs. 215.5 crore in cash against total borrowings of Rs. 26.5 crore.

For investors, this net cash disclosure often matters in two ways: it indicates financial flexibility for ongoing capex, and it frames how much incremental investment can potentially be funded internally.

Growth engines and guidance referenced in the material

The provided material describes Acutaas as a specialty chemicals manufacturer with a portfolio of over 610 products, catering to pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals.

Management guidance referenced includes a 25% revenue growth trajectory, described in multiple places as a consistent long-term stance. Growth drivers cited include:

• Electrolyte additive division (battery chemicals), including capacity of 2,000 MT for two products with long-term customer contracts
• Pharma intermediate business, described as the biggest growth engine
• Semiconductor chemical business, including BFC and Indichem JV, mentioned as a potential contributor in 2-3 years
• A CDMO business with a 10-year supply contract for the first customer, and additional validated products awaiting regulatory approval, each noted with peak revenue potential of Rs. 50-100 crore

Margins were also discussed in the supplied commentary, with an expectation that EBITDA margins may be maintained at FY26 levels, referenced as around ~42% quarterly / ~35% annual.

Stock and valuation snapshots cited

Multiple price and market-cap snapshots appear in the material. A “Quick Details” block lists CMP Rs. 3,654.2 and market cap Rs. 29,917.37 crore. Another snapshot cites shares trading at Rs. 3,695 and market cap Rs. 30,212 crore, along with a 12-month target range of Rs. 3,732-4,212 (Uniresearch estimate). Elsewhere, a data box shows current price Rs. 3,454 and market cap Rs. 28,282 crore, and another section mentions P/E values such as 62.8 and 79.4 in different contexts.

Because these are point-in-time readings from different sections, investors usually treat them as references and verify the latest values directly on exchange feeds.

Key numbers table

Historical quarterly financials shown (as provided)

The material also includes a quarterly table with figures in crores, presented below exactly in the stated periods.

What to track in filings and the conference call

The material notes that quarterly financials for this cycle may not yet be fully available on certain data partners, and suggests tracking Screener.in along with NSE/BSE filings directly for the confirmed result date and reported figures.

On the call, investors will likely focus on (1) commissioning progress and utilisation, (2) how management interprets demand under a stabilising pricing environment, (3) capex phasing and CWIP capitalisation, and (4) whether the company reiterates its growth and margin stance.

Conclusion

Acutaas Chemicals enters Q1 FY2026-27 with a strong Q4 FY2025-26 exit run-rate, a net cash position of about Rs. 189 crore, and active capex and commissioning milestones that could influence near-term margins. The key near-term events are the July 24, 2026 board meeting and the 4:00 PM IST earnings call hosted by Nuvama Wealth Management, where management’s commentary on revenue sustainability, project timelines, and margins will be closely watched.